Plan B Draws Criticism During Von Eschenbach Confirmation Hearing
This article was originally published in The Tan Sheet
Executive Summary
FDA's recent request to meet with Barr Labs about the proposed OTC sale of Plan B has done little to quell criticisms from Senate Democrats concerning the agency's extensive delays in issuing a decision on the Rx-to-OTC switch application
You may also be interested in...
FDA Depositions Reveal Crawford’s Prominent Role In Plan B Switch Review
The role of high-level FDA officials in the review of Barr Labs' Rx-to-OTC switch application for Plan B was required by the "high-profile" nature of the NDA, according to Center for Drug Evaluation & Research Director Steven Galson
Plan B Backlash Blocks FDA Commissioner Nomination: Take Two
FDA will not have a permanent commissioner until an actual decision is announced on the proposed Rx to-OTC switch of emergency contraceptive Plan B, if a hold by Senate Democrats is respected
Plan B Draws Criticism During Von Eschenbach Confirmation Hearing
FDA's recent request to meet with Barr Labs about the proposed OTC sale of Plan B has done little to quell criticisms from Senate Democrats concerning the agency's extensive delays in issuing a decision on the Rx-to-OTC switch application